


10/511886  
DT01 Rec'd PCT/INT 19 OCT 2004

**In the Claims:**

1. **(original)** Compound in the form of a pure optical isomer (1*R*,2*R*) or (1*S*,2*S*) or in the form of a threo diastereoisomer, corresponding to general formula (I)



in which A represents

either a group of general formula N-R<sub>1</sub> in which R<sub>1</sub> represents either a hydrogen atom, or a linear or branched (C<sub>1</sub>-C<sub>7</sub>)alkyl group optionally substituted with one or more fluorine atoms, or a (C<sub>4</sub>-C<sub>7</sub>)cycloalkyl group, or a (C<sub>3</sub>-C<sub>7</sub>)cycloalkyl(C<sub>1</sub>-C<sub>3</sub>)alkyl group, or a phenyl(C<sub>1</sub>-C<sub>3</sub>)alkyl group optionally substituted with one or two hydroxyl or methoxy groups, or a (C<sub>2</sub>-C<sub>4</sub>)alkenyl group, or a (C<sub>2</sub>-C<sub>4</sub>)alkynyl group,

or a group of general formula N<sup>+</sup>(O<sup>-</sup>)R<sub>1</sub> in which R<sub>1</sub> is as defined above,

or alternatively a group of general formula N<sup>+</sup>(R')R<sub>1</sub> in which R' represents a linear or branched (C<sub>1</sub>-C<sub>7</sub>)alkyl group and R<sub>1</sub> is as defined above,

X represents a hydrogen atom or one or more substituents chosen from halogen atoms and trifluoromethyl, linear or branched (C<sub>1</sub>-C<sub>4</sub>)alkyl and (C<sub>1</sub>-C<sub>4</sub>)alkoxy groups,

R<sub>2</sub> represents either a hydrogen atom, or one or more substituents chosen from halogen atoms and trifluoromethyl, (C<sub>1</sub>-C<sub>4</sub>)alkyl or (C<sub>1</sub>-C<sub>4</sub>)alkoxy groups, or amino groups of general formula NR<sub>3</sub>R<sub>4</sub> in which R<sub>3</sub> and R<sub>4</sub> each represent, independently of each other, a hydrogen atom or a (C<sub>1</sub>-C<sub>4</sub>)alkyl group, or form with the nitrogen atom carrying them a pyrrolidine, piperidine or morpholine ring, or a phenyl group optionally substituted with an atom or a group as defined for the symbol X above,

in the form of a free base or of an addition salt with an acid.

2. **(currently amended)** ~~Compound;~~ A compound according to Claim 1, ~~characterized in that wherein~~ it has the configuration (1*S*,2*S*) and in that R<sub>2</sub> represents one or more halogen atoms or trifluoromethyl groups.

3. **(currently amended)** ~~Compound,~~ A compound according to Claim 1, ~~characterized in that wherein~~ it has the configuration (1*R*,2*R*) and in that R<sub>2</sub> represents a halogen atom and an amino group of general formula NR<sub>3</sub>R<sub>4</sub> as defined in Claim 1.
4. **(cancelled)**
5. **(currently amended)** A Pharmaceutical composition, ~~characterized in that it contains comprising~~ a compound according to Claim 1 ~~one of Claims 1 to 3~~, combined with an excipient.
6. **(new)** 2-Chloro-*N*-[(*S*)-phenyl-[(2*S*)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide according to claim 1.
7. **(new)** 2-Chloro-*N*-[(*S*)-phenyl-[(2*S*)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide hydrochloride 1:1 according to claim 6.
8. **(new)** A pharmaceutical composition comprising a compound according to Claim 2 combined with an excipient.
9. **(new)** A pharmaceutical composition comprising a compound according to Claim 3 combined with an excipient.
10. **(new)** A pharmaceutical composition comprising a compound according to Claim 6 combined with an excipient.
11. **(new)** A pharmaceutical composition comprising a compound according to Claim 7 combined with an excipient.
12. **(new)** A method for the treatment of disorders in which glycine transporters are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 1.

13. **(new)** A method for the treatment of disorders in which glycine transporters are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 2.

14. **(new)** A method for the treatment of disorders in which glycine transporters are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 3.

15. **(new)** A method for the treatment of disorders in which glycine transporters are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 6.

16. **(new)** A method for the treatment of disorders in which glycine transporters are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 7.